1,3,5-Triaminohexane-2,4-diol

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1,3,5-Triaminohexane-2,4-diol
• 英文别名: 1,3,5-triaminohexane-2,4-diol
• 化学式: C₆H₁₇N₃O₂
• 分子量: 163.22
• InChiKey: LXOQVUPJJBNPNB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.3
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  119
• 氢给体数：
  5
• 氢受体数：
  5

文献信息

• Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
  申请人：Regeneron Pharmaceuticals, Inc.

  公开号：US20140013456A1

  公开（公告）日：2014-01-09

  A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of pH dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses human immunoglobulin light chain variable domains derived from a limited repertoire of human immunoglobulin light chain variable gene segments that comprise histidine modifications in their germline sequence. Methods of making non-human animals that express antibodies comprising histidine residues encoded by histidine codons introduced into immunoglobulin light chain nucleotide sequences are provided.
• CYSTIC FIBROSIS TREATMENT
  申请人：THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

  公开号：US20140242690A1

  公开（公告）日：2014-08-28

  The present invention relates to medicaments for the treatment of cystic fibrosis. Also provided are methods of preparing such medicaments so that they can be used in a treatment regime for cystic fibrosis. The present invention also provides a kit of parts including the medicament of the invention, as well as treatment regimes for cystic fibrosis.
• NEUTRALIZING GP41 ANTIBODIES AND THEIR USE
  申请人：The United State of America, as represented by the Secretary, Department of Health and Human Service

  公开号：US20140348785A1

  公开（公告）日：2014-11-27

  Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection.
• Compositions And Methods For Treating Steatohepatitis, Liver Fibrosis, and Hepatocellular Carcinoma (HCC)
  申请人：The Regents of the University of California

  公开号：US20150004133A1

  公开（公告）日：2015-01-01

  The invention provides methods and compositions for reducing symptoms of steatohepatitis and/or liver fibrosis and/or hepatocellular carcinoma (HCC) in a mammalian subject in need thereof, comprising administering to the mammalian subject a therapeutic amount of a compound that reduces the level of interleukin 17 (IL-17) and/or interleukin 23 (IL-23) and/or signal transducer and activator of transcription 3 (Stat3) and/or Janus kinase 2 (Jak2). The invention's methods may comprise administering to the mammalian subject a therapeutic amount of a compound that increase the level of interleukin 22 (IL-22) and/or interleukin 25 (IL-25) and/or interleukin 27 (IL-27). The invention's methods may comprise administering to the mammalian subject a therapeutic amount of interleukin 22 (IL-22) and/or interleukin 25 (IL-25) and/or interleukin 27 (IL-27).
• US9475862B2
  申请人：——

  公开号：US9475862B2

  公开（公告）日：2016-10-25